Pamidronate reduces bone loss after allogeneic stem cell transplantation

Area of Science:

• Bone Metabolism and Endocrinology
• Hematology and Oncology
• Pharmacology and Therapeutics

Background:

• Allogeneic stem cell transplantation (alloSCT) is frequently associated with rapid bone loss, particularly in the proximal femur.
• This bone loss can lead to increased fracture risk and negatively impact patient outcomes post-transplant.

Purpose of the Study:

• To evaluate the efficacy of high-dose pamidronate therapy in mitigating bone loss following alloSCT.
• To assess the impact of concurrent glucocorticoid and cyclosporin therapy on bone mineral density (BMD) changes.

Main Methods:

• A randomized, multicenter, open-label, 12-month prospective study involving 116 patients undergoing alloSCT.
• Patients received either intravenous pamidronate (90 mg/month) starting before conditioning or no pamidronate, alongside calcitriol and calcium supplementation.
• Changes in BMD at the femoral neck, lumbar spine, and total hip were compared between groups at 12 months post-transplant.

Main Results:

• Pamidronate significantly reduced bone loss at the spine, femoral neck, and total hip by 5.6%, 7.7%, and 4.9% respectively at 12 months (P ≤ 0.003).
• Despite pamidronate, BMD remained lower than baseline at the femoral neck (2.8%) and total hip (3.5%).
• Treatment benefits were most pronounced in patients receiving higher doses of prednisolone (>10 mg/day) and cyclosporin (>5 months).

Conclusions:

• High-dose pamidronate therapy markedly reduced, but did not completely prevent, bone loss after alloSCT.
• The bone-sparing effects were most significant in patients on intensive immunosuppressive therapy but were largely lost 12 months after pamidronate discontinuation.
• Further research into more potent bisphosphonates or anabolic agents like parathyroid hormone (PTH) is warranted for sustained bone mass maintenance post-alloSCT.